Amycretin (zenagamtide)

Investigated uses

• Obesity, overweight and type 2 diabetes in clinical development.

Mechanism and hypotheses

• Zenagamtide is designed as one molecule that activates GLP-1 and amylin receptors.

Human evidence

• A randomized, double-blind, placebo-controlled Phase 2 program evaluated once-weekly subcutaneous zenagamtide in adults with type 2 diabetes. Limitations: Sponsor reporting does not replace full peer-reviewed publication, regulatory review or long-term surveillance.

Safety highlights

• The adverse-event profile remains investigational and is still being characterized in later-stage trials.
• Long-term and uncommon risks are not established because no approved label or postmarketing record exists.

Regulatory context

Investigational; no FDA-approved amycretin product.